The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration
Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (H...
Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular c...
Sorafenib is associated with multiple adverse events (AEs), potentially causing its permanent interr...
The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changi...
For a decade, sorafenib remained the only approved first-line treatment and standard of care for adv...
Introduction Hepatocellular carcinoma (HCC) is rare in non-cirrhotic liver. Achievement of sustaine...
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common c...
Hepatocellular carcinoma (HCC) is the third leading cause of death by cancer worldwide. The prognosi...
Jörg Trojan, Oliver Waidmann Medizinische Klinik 1, Universitätsklinikum Frankfu...
Systemic therapy of advanced stage hepatocellular carcinoma (HCC) was limited to the sorafenib in th...
Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the introduction o...
none24siPublished Online December 5, 2016Background: There are no systemic treatments for patients w...
Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to sorafenib, whic...
Hepatocellular carcinoma (HCC) is an aggressive cancer associated with high mortality worldwide. HCC...
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the main cause of cancer-...
Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (H...
Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular c...
Sorafenib is associated with multiple adverse events (AEs), potentially causing its permanent interr...
The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changi...
For a decade, sorafenib remained the only approved first-line treatment and standard of care for adv...
Introduction Hepatocellular carcinoma (HCC) is rare in non-cirrhotic liver. Achievement of sustaine...
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common c...
Hepatocellular carcinoma (HCC) is the third leading cause of death by cancer worldwide. The prognosi...
Jörg Trojan, Oliver Waidmann Medizinische Klinik 1, Universitätsklinikum Frankfu...
Systemic therapy of advanced stage hepatocellular carcinoma (HCC) was limited to the sorafenib in th...
Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the introduction o...
none24siPublished Online December 5, 2016Background: There are no systemic treatments for patients w...
Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to sorafenib, whic...
Hepatocellular carcinoma (HCC) is an aggressive cancer associated with high mortality worldwide. HCC...
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the main cause of cancer-...
Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (H...
Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular c...
Sorafenib is associated with multiple adverse events (AEs), potentially causing its permanent interr...
DOI
Add to ORKG